👉SXTP is TODAY’S #1 ALERT 👈

Hey Folks, Jeff Bishop here.

My “tactical trade” ideas are on fire 🔥 this week.

I dished out two double-digit winners on Monday. One of them surged 31% higher intraday.

I took the day off Tuesday, but yesterday I alerted a uranium-focused stock that settled at a 9% gain by the closing bell, then kept ripping after hours:

Right now I have my eye on a very small stock that’s up 40% since its recent low last Tuesday.

💥Go ahead and pull up 60 Degrees Pharmaceuticals, Inc. (SXTP) on your favorite trading platform.

The play here is simple…

SXTP had been on a tear already, but the company just announced big news yesterday (more on that below) that sent its stock as much as 28% higher than its $2.86 closing price.

And if you take a look, the stock spent much of April above that $2.86 level, telling me there’s plenty of room to the upside.

I’m watching SXTP to see if its killer momentum carries it higher today.

👉  SXTP is TODAY’S #1 ALERT 👈

SXTP is a Washington, D.C.-based company founded in 2010, focused on developing and marketing medicines for infectious diseases.

Its flagship product, ARAKODA® (tafenoquine), received FDA approval in 2018 for malaria prevention.

Here are the five most important things about SXTP that investors should have on their radars:

1. ARAKODA®: The Only Weekly Malaria Prophylactic Covering All Stages 🦟

SXTP developed ARAKODA® (tafenoquine), the only weekly malaria prophylactic approved in the U.S. that targets both blood and liver stages of malaria.

This is a significant advancement over daily regimens, offering convenience and comprehensive protection. 

Just yesterday, the company introduced an 8-count bottle format, catering to short-term travelers to malaria-endemic regions. The bottles are now available through major retail pharmacies, including Amazon Pharmacy.

2. Expanding Tafenoquine’s Use to Treat Babesiosis 🧬

Beyond malaria, SXTP is exploring tafenoquine’s potential in treating babesiosis — a tick-borne disease similar to malaria. 

In January, the company secured approval for a Phase II trial targeting chronic babesiosis patients suffering from severe fatigue. 

This initiative is particularly noteworthy as babesiosis cases are reportedly ten times higher than CDC estimates, indicating a significant unmet medical need. 

Patient enrollment is expected to begin in Q3 2025.

Strategic Collaborations with Prestigious Institutions 🏥

In April, the company announced a collaboration with Yale School of Medicine and Yale School of Public Health “to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.”

That follows its December 2024 clinical trial agreement with Brigham and Women’s Hospital to evaluate “the safety and efficacy of tafenoquine in combination with standard of care treatment for hospitalized babesiosis patients.”

These partnerships aim to advance the development of tafenoquine for babesiosis treatment and prevention, leveraging academic expertise to accelerate research. 

4. Robust Financial Growth Amidst Challenges 📈

In 2024, 60 Degrees reported a 140% increase in net product revenues, totaling $607,000, primarily driven by ARAKODA® sales. 

The first quarter of 2025 continued this positive trend with a 55% year-over-year revenue increase. 

While operating expenses have risen, the company’s ability to secure funding, including a recent $1.043 million direct offering in January and a $1.075 million direct offering in February demonstrates financial resilience. 

5. Leadership with Deep Expertise in Infectious Diseases 🧠

CEO Geoffrey Dow brings more than two decades of experience in tropical disease product development, including significant roles at the Walter Reed Army Institute of Research. 

His leadership has been instrumental in securing FDA approval for ARAKODA® and steering the company’s strategic direction. 

Final Thoughts

Just this Monday, analysts at Ascendiant Capital gave SXTP a $7.00 price target — 144% higher than yesterday’s closing price — and maintained its “BUY” rating. 

As you do your own research on SXTP, be sure to check out its April 1 investor presentation and the company website.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

SXTP has ripped 40% since last Tuesday but it still has considerable room to the upside compared to its valuation through much of April.

💥Stay locked in to SXTP to see if its momentum carries it higher today.

To Your Success,

Promoted by Shore Thing Media

DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, Sherwood Ventures has received five thousand dollars (cash) from Shore Thing Media for a one day marketing program starting on June 5, 2025. Previously, Sherwood Ventures has received ten thousand dollars (cash) from Shore Thing Media, for a one day marketing program starting on March 8, 2025. These amounts were paid by someone else not connected to 60 Degrees Pharmaceuticals. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into 60 Degrees Pharmaceuticals might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s up to you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional investment advisor.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, broker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regulatory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.